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1. INTRODUCTION
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are 
the most prescribed drugs over years in various conditions like 
pain, arthritis, osteoarthritis and other medical conditions1. They 
show anti-inflammatory, antipyretic and analgesic properties by 
inhibiting the synthesis of prostaglandins via cyclooxygenase 
pathway2,3. Yet there are some side effects related to the use 
of NSAIDs like gastric ulcers, gastrointestinal bleeding and 
recently it has also been found that continuous use of NSAIDs is 
also linked to cardiovascular diseases4. Despite many advances 
in the prevention and management, cardiovascular diseases 
still remain the leading cause of morbidity and mortality 
in individuals5. The main target for the action of NSAIDs is 
cyclooxygenase (COX) enzyme, which is the key enzyme 
for the synthesis of prostaglandins (PGs)6. Cyclooxygenase 
enzyme acts on arachidonic acid (C-20:4) released from 
sn-2 position of the phospholipids present on cell membrane 
through the action of phospholipase A2 during inflammation7. 
Cyclooxygenase enzyme catalyzes the double dioxygenation 
of arachidonic acid via two reactions, first a cyclooxygenation 
reaction in which an oxygen molecule binds to arachidonic 
acid to form prostaglandin G2 and second a peroxidation 
reaction where prostaglandin G2 is reduced to a more stable 
prostaglandin H28. There are two isoforms of cyclooxygenase 
enzyme (cyclooxygenase-1 and cyclooxygenase-2) which differ 
in their active site due to an isoleucine to valine substitution at 
amino acid 523 in cyclooxygenase-29. This substitution makes 
cyclooxygenase-2 more permissive to utilize other fatty acids 
in addition to arachidonic acid10. Cyclooxygenase enzymes are 
homodimeric in nature and each dimer subunit consists of three 
domains, namely the membrane binding domain, the epidermal 
growth factor binding domain, and the catalytic domain11. 
Cyclooxygenase-1 is constitutively expressed in various cells 
like platelets, endothelial lining of stomach, kidneys, etc. but 
expression of cyclooxygenase-2 depends on other factors like 
shear stress, inflammatory mediators, etc.12.
2. SYNTHESIS OF PROSTAGLANDINS
The prostanoids belong to the oxylipin family of lipids 
synthesised by specific prostaglandin synthase enzyme which 
confer stereo specificity and chirality on every functional 
group13. The naming of each prostaglandin is done by prefixing 
‘PG’ followed by a letter A to K that depends on position and 
nature of substituents on their ring14 as shown in Fig. 2. The 
total numbers of double bonds in the alkyl substituents are 
denoted by a numerical suffix (1 to 3), where the numbering 
depends on the nature of the precursor fatty acid15.
Prostaglandins are produced by cyclooxygenase enzyme 
inside the cell as the signal passes from the membrane receptor 
causing an increase in intracellular concentration of arachidonic 
acid via calcium-dependent phospholipase A216. First molecule 
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as an agonist for platelet aggregation22. It also mobilizes 
calcium ions from intracellular storage sites and triggers 
platelet granules to release active substances like-
thromboglobulin, coagulation factor VIII, von Willebrand 
factor, fibrinogen, and ADP23. Thromboxane directs 
different biological processes like vasoconstriction, 
endothelial adhesion molecules expression and 
proliferation via its cell surface receptor TP24. On the 
other hand Prostacyclins exert multiple vasoprotective 
effects in the cardiovascular system by vasodilation and 
inhibition of platelet aggregation similar to the action 
of endothelium-derived nitric oxide (NO)25. Enzymes 
required for the production of prostacyclins are localised 
around the nuclear membrane and on the endoplasmic 
reticulum of the vascular endothelial cells26. An increase 
in intracellular calcium is required for activation of 
cytoplasmic PLA2. Shear stress in the endothelium activates the 
cytoplasmic PLA2 which removes arachidonic acid from the 
membrane, which is acted upon by cyclooxygenase-2 and thus 
gets converted into prostacyclins with the help of prostaglandin 
I synthase27. Prostacyclins increase the concentration of 
cAMP which is the inhibitor of platelet aggregation28. They 
also inhibit the expression of platelet activation markers like 
platelet fibrinogen receptor, P-selectin, platelet-leukocyte 
aggregation, and granular release of serotonin29 . Shear stress 
also leads to generation of nitric oxide via endothelial nitric 
oxide synthase, which in turn inhibits platelet aggregation by 
increasing the production of cGMP and suppressing the action 
of thromboxane synthase30. This action by endothelial cells 
masks the action of thromboxane formed in the platelets and 
maintains the integrity of the vascular wall31.
As shown in Fig. 4, in normal homeostasis prostacyclins 
are continuously formed by the cyclooxygenase-2 action in the 
Figure 1.   Glycosylation sites in cyclooxygenase-1 and cyclooxygenase-2. 
(Sp- signal peptide, Dm- dimerization domain, EG- epidermal 
growth factor domain, Mb- membrane binding domain, 
Cat-catalytic domain, and MTS- membrane targeting 
sequence).
Figure 2.  Structure of prostaglandins, prostacyclins (PGI) and 
thromboxane (TXA, TXB). 
formed from cyclooxygenase enzyme is prostaglandin 
G2 which immediately gets converted to more stable 
prostaglandin H2 which acts as the precursor for 
the formation of all other prostanoids by different 
enzymatic reactions17 as shown in Fig. 3. Prostacyclin 
synthase converts prostaglandin H2 to prostaglandin 
I2, while thromboxane A synthase catalyzes the 
production of thromboxane from prostaglandin H2 in 
different cells18. Cyclooxygenase-2 enzyme remains 
active in vascular endothelial cells due to the shearing 
stress resulting in the production of prostacyclins which 
act as vasodilator and inhibit platelets aggregation19. 
Whereas cyclooxygenase-1 which is constitutively 
expressed in platelets, leads to the production of 
thromboxane where it acts as a vasoconstrictor and 
promotes platelet aggregation20. 
     
3. MECHANISM OF ACTION 
OF THROMBOXANE AND 
PROSTACYCLINS
Thromboxane is predominantly synthesised in 
the platelets with the help of thromboxane synthase21. 
Thromboxane increases the G-protein activation 
which releases ADP from dense granules, which acts 
Figure 3. Generation of prostaglandins from arachidonic acid via action of 
cyclooxygenase enzyme.
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increases the cytosolic concentration of Ca2+ which binds to 
PLA2 and releases arachidonic acid on which cyclooxygenase 
enzyme acts and thromboxane is generated. As thromboxane 
is generated, it comes out of the platelets and binds to other 
platelet membrane receptors and leads to the production of 
more thromboxane and thus causes platelet aggregation.
4. BALANCE BETWEEN 
PROSTACYCLIN AND THROMBOXANE 
IN CARDIOVASCULAR DISEASES
During vascular injury, ADP and thrombin 
are released from adherent platelets which results 
in activation of cytoplasmic PLA2 and generation 
of thromboxanes32. Many studies have established 
thromboxane as a mediator in cardiovascular 
diseases33. Aspirin irreversibly inhibits platelet 
cyclooxygenase, even when given in low doses, thus 
being used as an antiplatelet therapy for the preventing 
vascular thrombotic events and indicating the role of 
thromboxane as a platelet agonist in cardiovascular 
diseases34. Prostacyclins have vasodilatory as well 
as antithrombotic effects which are opposed by 
thromboxanes35. Knockout mice for prostacyclin 
receptor showed propensity towards atherosclerosis, 
increased thrombosis, and proliferative response 
to carotid vascular injury36. Mice knocked out for 
both, prostacyclins and thromboxanes receptors, had 
similar vascular remodeling as wild-type control 
mice37. Deletion of prostacyclin receptors led to 
aggregation of platelets and did not inhibit thrombus 
formation38. Prostacyclin concentration remains 
higher in normal homeostasis so that it can prevent 
platelet aggregation but in case of vascular injury, 
endothelial cells are no longer able to produce 
prostacyclin due to which thromboxane production 
from platelets increases platelet aggregation39.
5. NSAIDS MECHANISM 
OF ACTION AND RISKS 
ASSOCIATED WITH THEM 
NSAIDs are having  anti-
inflammatory, analgesic and antipyretic 
activity and they achieve their effect 
by inhibiting prostaglandin synthesis40. 
NSAIDs vary in their selectivity for 
the cyclooxygenase-1 and 2, hence 
are categorised as nonselective, semi 
selective and selective cyclooxygenase 
inhibitors41. Non selective NSAIDs 
like aspirin, ibuprofen and naproxen, 
inhibit both isoforms of cyclooxygenase 
enzyme and among them, aspirin 
irreversibly inhibits the cyclooxygenase 
activity42. At low therapeutic doses, 
aspirin is up to 100-fold more potent 
in inhibiting platelet cyclooxygenase-1 
than cyclooxygenase-2 by covalent 
acetylation of serine residues in their 
Figure 4.   Normal homeostasis in platelets and changes that occurs in platelets 
during vascular injury. 
vascular endothelial cells and bind to the IP receptor on platelets 
which causes an increase in the intracellular concentration 
of cAMP that suppresses the cytosolic concentration of Ca2+ 
and hence blocks the generation of thromboxane. In case of 
vascular injury, platelets bind to the exposed collagen with the 
help of vWF, which activates phospholipase. Phospholipase 
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active sites that leads to permanent inhibition of cyclooxygenase 
enzyme activity43. Aspirin exhibits cardio protective effects 
by inhibiting platelet aggregation in the arteries of the heart, 
but administration of non-selective NSAIDs are associated 
with serious conditions like peptic ulcers and gastrointestinal 
bleeding because blocking of cyclooxygenase enzyme in 
stomach leads to disruption of the integrity of the stomach 
lining and blocking the same in kidneys has a decisive role in 
the regulation of glomerular filtration44. 
In a cohort study in a group of 52,293 patients taking 
NSAIDs, the relative risk of hospitalisation for upper GI 
problems was 3.9 (2.93-4.78)45. Naproxen mimics the activity 
of acetylsalicylic acid (aspirin) by suppressing platelet 
cyclooxygenase, but the role of naproxen in the development 
of CVD is controversial46. It has been suggested that ibuprofen 
is strongly associated with the cardiovascular risks similar 
to that of celecoxib (a selective NSAID)47. A second class 
of NSAIDs (diclofenac, indomethacin, melaxicam) inhibits 
cyclooxygenase-2 up to a greater extent as compared to 
cyclooxygenase-1 hence called semi-selective NSAIDs, but 
any evidence of it being associated with cardiovascular diseases 
is not known48. Diclofenac has been shown to increase the 
occurrences of myocardial infarction and stroke even at lower 
doses than naproxen at a higher dose49. Cardiovascular risks 
associated with the use of meloxicam are still unknown, as the 
number of trials assessing meloxicam are very limited50. Another 
class of NSAIDs (celecoxib and rofecoxib) selectively inhibit 
cyclooxygenase-2, hence are termed as selective NSAIDs51. 
Selective NSAIDs are recommended for the patients who have 
painful intestinal bleeding problems52. The VIGOR study for 
assessing the risk of gastrointestinal events on administration 
of selective NSAIDs showed that the risk of development of 
gastrointestinal events was lower in the case of rofecoxib as 
compared to naproxen53. However, prolonged exposure to any 
class of NSAIDs, (irrespective of their mechanism of action) 
has unveiled potential adverse effects on cardiovascular events, 
depending on the dosage and duration of these drugs, in patients 
having or not having preexisting cardiovascular conditions54. 
Rofecoxib contains a methylsulfonyl group in place of 
carboxyl group of NSAIDs which binds to the hydrophobic 
region in the active binding site of cyclooxygenase-255. Even 
in very small doses, Rofecoxib inhibits the synthesis of 
prostacyclins by selectively inhibiting cyclooxygenase-2 and 
allowing the formation of thromboxane in platelets, which 
increases the risk of cardiovascular diseases56. The VIGOR 
study was performed to evaluate the cardiovascular safety 
of rofecoxib as compared to naproxen in which 8076 people 
volunteered and calculated relative risk was 2.37 (1.39- 
4.06) with rofecoxib57. Similarly, in the Adenomatous Polyp 
Prevention on Vioxx (APPROVe) study which was done 
to analogize rofecoxib and placebo, an increased episode of 
thrombotic events explicitly myocardial infarction and stroke, 
with rofecoxib therapy was observed58. 
Another selective NSAID, colecoxib contains a 
sulfonamide group in place of a carboxyl group but risks 
associated with smaller doses of celecoxib are not clear so 
far59. A meta-analysis of randomised control trials comparing 
the risks involved in taking selective NSAIDs with those in 
other non-selective NSAIDs and placebo was performed on 
a total of 116,429 patients. In this study, acute myocardial 
infarction (AMI) was considered as the primary outcome 
and the results for three non-selective NSAIDs (naproxen, 
ibuprofen, diclofenac) and two coxibs (rofecoxib, celecoxib) 
was statistically evaluated in which the highest risk of AMI 
as compared to placebo was associated with ibuprofen (RR 
= 1.61; 0.50-5.77) and rofecoxib (RR = 2.12; 1.26-3.56)60. 
Recently, in a meta-analysis of 23 controlled observational 
studies (six cohorts and 17 case-controls), 75,520 coxibs users 
and 375,619 users of nonselective NSAIDs were compared 
to 594,720 patients with absolutely no exposure to NSAIDs 
and it was analysed that out of all non-selective NSAIDs, the 
maximum risk for cardiovascular diseases was contingent on 
diclofenac (RR = 1.40; 1.16-1.70) and the safest was naproxen 
(RR = 0.9; 0.87- 1.07) and in case of rofecoxib (RR = 1.35; 
1.15-1.59), the risk was significantly influenced by the dose61. 
6. CONCLUSION
Cardiovascular diseases remain the pivotal topic of 
research as it is one of the leading causes of mortality all over 
the world. There are different mechanisms by which it occurs 
but alteration of cyclooxygenase pathway can be regarded as an 
important one. In normal homeostasis, endothelial cells produce 
prostacyclins by the action of cyclooxygenase-2 enzyme, which 
maintains the integrity of endothelial cells through inhibition of 
platelet aggregation and vasodilation. During vascular injury, 
platelets bind to collagen with the help of vWF and increase 
cytosolic calcium ion concentrations, activating cytoplasmic 
PLA2 which ultimately leads to the formation of thromboxane. 
NSAIDs are the drugs which are used worldwide by patients 
for cardiovascular diseases. These drugs inhibit the action of 
cyclooxygenase enzyme directly and further block the formation 
of thromboxane and prostacyclins. Among the NSAIDs, non-
selective NSAIDs inhibit both the isoforms of cyclooxygenase 
hence they are associated with the greater risk of peptic 
ulcers and gastrointestinal bleeding. Naproxen also mimics 
the action of aspirin by blocking cyclooxygenase-1 enzyme 
but its association with cardiovascular risks is controversial. 
Ibuprofen is strongly associated with the cardiovascular risks 
similar to other selective NSAIDS. Diclofenac is associated 
with myocardial infarction even at very small doses and risk 
associated with meloxicam is not known due to limited number 
of trials. Selective NSAIDs (like rofecoxib and celecoxibs), are 
used for those patients who have intestinal bleeding problems 
but their use is strongly associated with the cardiovascular risks. 
Both selectively inhibit the COX-2 enzyme and the formation 
of prostacyclins in the endothelial cells. From the above data it 
can be concluded that selective COX-2 inhibitors are strongly 
associated with the cardiovascular risks as compared to the 
non-selective NSAIDs.
7. FUTURE PROSPECTS
NSAIDs have various side effects in patients with 
cardiovascular conditions because they may cause hemorrhagic 
events. The chances of these associated side effects are more 
in those patients taking NSAID monotherapy and also in those 
taking concomitant antiplatelet and/or anticoagulant therapies, 
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target-specific oral anticoagulants and vitamin K antagonists. 
Hence, the understanding of probable danger associated with 
the use of NSAIDs in patients who have cardiovascular risk 
factors is crucial. It has been stated that risk of cardiovascular 
diseases with NSAIDs appears to augment as the dosage and 
period of therapy increases. For NSAID therapy, a careful 
assessment of the individual risks and benefits should be 
conducted before prescribing the lowest effective dose for 
the shortest duration of time. Although patients should also 
be educated on the risks of continued NSAID therapy and the 
importance of reporting all the NSAIDs used during medical 
history. So, it can be concluded that there is no such COX 
inhibitor present so far that has minimum or no side effects 
and can be used widely. As such, various aspects of NSAID 
induced cardiotoxicity still need to be investigated; including 
the significance of NSAID induced cardiovascular risks, so 
that an accurate and competent drug can be formulated in near 
future that could reduce the side effects of NSAIDs.
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